Non-invasive electrocardiographic imaging (ECGi) with VIVO accurately localized the arrhythmogenic substrate for scar-dependent VT, achieving a complete match with electro-anatomical maps in 67% of VTs.
Observational (n=31)
Blinded analysis
Does non-invasive electrocardiographic imaging (ECGi) accurately localise the arrhythmogenic substrate compared to electro-anatomical mapping in patients with scar-dependent ventricular tachycardia?
Non-invasive ECGi mapping with VIVO accurately predicts the arrhythmogenic substrate for scar-dependent VT, which may improve procedural efficiency during ablation.
Abstract Background and aims Accuracy data for non-invasive electrocardiographic imaging (ECGi) in defining the arrhythmogenic substrate for scar-dependant ventricular tachycardia (VT) is lacking. This study evaluated the accuracy of ECGi mapping to localise the arrhythmogenic substrate and assessed the relationship to myocardial scar, isthmus, exit and successful ablation sites. Methods A total of 48 VTs in 31 patients were mapped with both ECGi (View into Ventricular Onset, VIVO) and electro-anatomical maps (EAM) to define the arrhythmogenic substrate. Myocardial segments were assigned for the VT-exit site region (VT-ESR), isthmus region, successful ablation sites and cardiac cross-sectional imaging defined scar using the ventricular AHA segment model and underwent blinded analysis. Results VT-ESR complete match (defined as exact AHA segment concordance between ECGi and EAM) was seen in 67% and partial match (defined as adjacent segments) in 21% of VTs. ECGi VT-ESR was located within or adjacent to cross-sectional imaging defined scar in 85% of VTs. The VT isthmus was within or adjacent to the ECGi VT-ESR in 77% of VTs. Successful ablation sites were within or adjacent to the ECGi VT-ESR in 82% of VTs. VIVO ECGi accuracy was not affected by cardiomyopathy type or VT cycle length. In identifying epicardial VT-ESR for ischaemic cardiomyopathy, VIVO ECGi had a sensitivity and specificity of 71.4% and 92.9%; for non-ischaemic cardiomyopathy 66.7% and 100%, respectively. Conclusion ECGi mapping with VIVO can accurately predict the arrhythmogenic substrate for scar-dependent VT. Incorporation of ECGi mapping to conventional VT ablation workflows may improve procedural efficiency.
Al-Sheikhli et al. (Wed,) conducted a observational in Scar-dependent ventricular tachycardia (n=31). Non-invasive electrocardiographic imaging (ECGi, VIVO) vs. Electro-anatomical maps (EAM) was evaluated on VT-exit site region (VT-ESR) complete match between ECGi and EAM. Non-invasive electrocardiographic imaging (ECGi) with VIVO accurately localized the arrhythmogenic substrate for scar-dependent VT, achieving a complete match with electro-anatomical maps in 67% of VTs.